Evaluation of Safety, Tolerability, and Pharmacokinetics of Topical Ocular DS101 in Diabetic Retinopathy: A Phase I Randomized, Double-Blind, Placebo-Controlled Study

The primary objective of this clinical trial is to evaluate the **safety**, **tolerability**, and **pharmacokinetics** of topical ocular administration of DS101 in healthy subjects. This is a Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group study. The clinical relevance of this study lies in its potential to inform future research and development of treatments for **diabetic retinopathy**, a condition that can lead to vision loss if not effectively managed. No secondary objectives are provided for this study.

The clinical trial focuses on participants diagnosed with **diabetic retinopathy**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. The trial does not involve a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria for the trial population, as well as specific lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Key inclusion or exclusion criteria are also not specified by the sponsor.

This clinical trial is a **Phase I**, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety, tolerability, and pharmacokinetics of topical ocular administration of DS101 in healthy subjects. The trial targets **diabetic retinopathy** and is scheduled to commence recruitment on March 3, 2025, with an estimated completion date of September 24, 2025. The study will involve a series of visits, beginning with an inclusion visit where participants will undergo screening to determine eligibility based on predefined criteria. This will be followed by multiple study visits where participants will receive either the investigational product or placebo, with both the participants and investigators blinded to the treatment allocation to ensure unbiased results.

Throughout the trial, participants will attend follow-up visits to monitor safety and collect pharmacokinetic data. These visits are crucial for assessing the drug's effects and any adverse reactions. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to gather comprehensive data on the investigational product's safety profile. The expected duration of participant involvement will align with the trial's overall timeline, from the initial screening to the end-of-study visit. Conditions that may lead to early termination from the study include the occurrence of significant adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial's design and procedures are structured to ensure rigorous evaluation of the investigational product while maintaining participant safety and data integrity.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for both experimental and non-experimental treatments is not available in the provided data.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is March 3, 2025, with an anticipated end date of September 24, 2025. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. These assessments may include measuring changes in **biomarker** levels or initial symptom improvement, depending on the investigational product and disease context. The methods for measuring and analyzing efficacy would typically involve validated scales or laboratory tests, conducted at predetermined timepoints throughout the trial duration. The data collected will be analyzed to determine the potential therapeutic effects of the investigational product, guiding further clinical development in subsequent trial phases.